Savara (SVRA) Return on Capital Employed (2011 - 2026)
Savara (SVRA) reported Return on Capital Employed of 60.41% for Q1 2026, down 271.0% year-over-year from 35.33% in Q1 2025, and up 13.57% quarter-over-quarter from 69.89% in Q4 2025.
Savara (SVRA) Return on Capital Employed (2011 - 2026) Analysis & Trends
Savara (SVRA) has 16 years of Return on Capital Employed data on file, last reported at 60.41% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 60.41%, down 271.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 60.41% (down 271.0% YoY), and the FY2025 annual result was 58.07%, down 90.0% from the prior year.
- Return on Capital Employed advanced to 60.41% in Q1 2026 per SVRA's latest filing, from 69.89% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 24.11% in Q2 2022 and troughed at 89.47% in Q3 2025.
- A 5-year average of 47.12% and a median of 44.5% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2022 and 2025: Return on Capital Employed jumped 467 bps in 2022, then tumbled 3866 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 28.16% in 2022, then fell by 26 bps to 35.46% in 2023, then tumbled by 38 bps to 48.88% in 2024, then slumped by 43 bps to 69.89% in 2025, then rose by 14 bps to 60.41% in 2026.
- Business Quant data shows SVRA's Return on Capital Employed at 60.41% in Q1 2026, 69.89% in Q4 2025, and 89.47% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Savara | 1.39 Bn | 1.39 Bn | - | -60.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -60.41% |
| Dec 31, 2025 | -69.89% |
| Sep 30, 2025 | -89.47% |
| Jun 30, 2025 | -72.07% |
| Mar 31, 2025 | -57.69% |
| Dec 31, 2024 | -48.88% |
| Sep 30, 2024 | -50.81% |
| Jun 30, 2024 | -59.07% |
| Mar 31, 2024 | -44.50% |
| Dec 31, 2023 | -35.46% |
| Sep 30, 2023 | -37.50% |
| Jun 30, 2023 | -38.53% |
| Mar 31, 2023 | -33.09% |
| Dec 31, 2022 | -28.16% |
| Sep 30, 2022 | -26.24% |
| Jun 30, 2022 | -24.11% |
| Mar 31, 2022 | -25.22% |
| Dec 31, 2021 | -24.80% |
| Sep 30, 2021 | -24.20% |
| Jun 30, 2021 | -22.74% |